Alpine Immune Sciences Inc (ALPN)
64.96
-0.01
(-0.02%)
USD |
NASDAQ |
May 16, 16:00
64.98
+0.02
(+0.03%)
After-Hours: 20:00
Alpine Immune Sciences Research and Development Expense (TTM): 83.78M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 83.78M |
| December 31, 2023 | 80.90M |
| September 30, 2023 | 76.73M |
| June 30, 2023 | 75.17M |
| March 31, 2023 | 73.51M |
| December 31, 2022 | 70.24M |
| September 30, 2022 | 66.85M |
| June 30, 2022 | 67.57M |
| March 31, 2022 | 64.62M |
| December 31, 2021 | 58.74M |
| September 30, 2021 | 52.44M |
| June 30, 2021 | 40.28M |
| March 31, 2021 | 32.74M |
| December 31, 2020 | 27.18M |
| September 30, 2020 | 23.93M |
| June 30, 2020 | 27.30M |
| March 31, 2020 | 30.38M |
| December 31, 2019 | 35.85M |
| September 30, 2019 | 38.98M |
| Date | Value |
|---|---|
| June 30, 2019 | 39.98M |
| March 31, 2019 | 35.53M |
| December 31, 2018 | 28.97M |
| September 30, 2018 | 23.75M |
| June 30, 2018 | 15.97M |
| March 31, 2018 | 10.61M |
| December 31, 2017 | 9.577M |
| September 30, 2017 | 11.52M |
| June 30, 2017 | 14.44M |
| March 31, 2017 | 20.51M |
| December 31, 2016 | 23.32M |
| September 30, 2016 | 21.95M |
| June 30, 2016 | 20.56M |
| March 31, 2016 | 18.60M |
| December 31, 2015 | 16.05M |
| September 30, 2015 | 14.58M |
| June 30, 2015 | 12.47M |
| March 31, 2015 | 11.37M |
| December 31, 2014 | 12.20M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
23.93M
Minimum
Sep 2020
83.78M
Maximum
Mar 2024
53.36M
Average
55.59M
Median
Research and Development Expense (TTM) Benchmarks
| Vertex Pharmaceuticals Inc | 3.209B |
| Eliem Therapeutics Inc | 15.41M |
| Regeneron Pharmaceuticals Inc | 4.586B |
| Vera Therapeutics Inc | 76.32M |
| Eyenovia Inc | 12.98M |